Admission of Further Securities to Trading

Summary by AI ^BETAClose X

AstraZeneca admitted 11,948 ordinary shares of $0.25 each to trading on the London Stock Exchange Main Market for the period 1–31 October 2026 under its existing block admission, raising total shares outstanding to 1,551,065,237 and diluting equity by approximately 0.00077%; the shares are fully fungible, were issued under employee share schemes and no prospectus or supplement was published, meaning the issuance is de minimis and unlikely to have a material impact on EPS or market capitalization.

Disclaimer*

1	Details of the issuer
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
2	Details of the transferable securities admitted to trading
a)	Name, type and identification code	Ordinary Shares of $0.25 each ISIN: GB0009895292
b)	Regulated market	London Stock Exchange - Main Market
c)	Number of further securities issued and admitted	11,948
d)	Total number of securities in issue following admission	1,551,065,237
e)	Fungibility	Fully fungible with existing Ordinary Shares
3	Admission details
a)	Date of admission	Issued between 1 October 2026 to 31 October 2026 (admitted under a block admission dated 29 January 2021)
b)	Prospectus information	Prospectus: N/A Supplementary: N/A Company's webpage: https://www.astrazeneca.com
c)	Coverage of notification	Admission of shares under the Company’s employee share schemes from 1 October 2026 up to 31 October 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company’s existing block admission of shares dated 29 January 2021.

Summary by AI ^BETAClose X

Companies

UK 100

Latest directors dealings

Admission of Further Securities to Trading

Summary by AI BETAClose X

Companies

UK 100

Latest directors dealings

Summary by AI ^BETAClose X